Targeted radiation therapy for advanced cancers with SSTR2 and integrin markers
Part of Cancer clinical trials.
This trial tests a new radioactive drug (177Lu-TATE-RGD) that targets two specific markers on tumor cells. It is for people whose cancer has not responded to standard treatments and whose tumors show high levels of these markers on a PET scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a cancer that is confirmed by a biopsy and standard treatments have stopped working or are not suitable.
- A special PET scan (68Ga-TATE-RGD) must show your tumor has high levels of two specific markers (SSTR2 and integrin αVβ3).
- Your kidneys, liver, and blood cell counts need to be within certain healthy limits (doctor will check).
- You must not have significant heart valve disease caused by your tumor.
- You cannot have severe allergies to contrast dye or claustrophobia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a targeted radioactive medicine (177Lu-AB-3PRGD2) can shrink or control tumors that strongly match a specific target seen on special scans. It may help people whose current standard treatments are not working or are no longer working.
This trial tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy drug (Tislelizumab) as maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC) whose tumors have a specific protein (SSTR). If you have completed first-line treatment and your cancer shows SSTR on a PET scan, this study may be an option.
This study uses a special type of PET scan (called SSTR PET/CT) to look at tumors that may have a specific receptor. The scan helps doctors see where these tumors are and how active they are.
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This study tests two new radioactive drugs designed to find and image advanced breast or prostate cancer. The drugs use special imaging scans (PET and SPECT) to locate tumors and may help guide future treatment decisions.
Hear when a new SSTR2 and Integrin αVβ3 Positive Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.